Abstract
CSF somatostatin and homovanillic acid (HVA) were measured in 14 schizophrenic patients while they were drug-free and during chronic fluphenazine treatment. CSF somatostatin was significantly reduced and CSF HVA was significantly elevated (p <0.002) during fluphenazine treatment. There was a trend toward correlation between CSF somatostatin and CSF HVA in the 14 schizophrenic patients when drug-free (r = 0.49, p <0.07) and fluphenazine-treated (r = 0.47, p <0.08). When examined in a larger group (n = 46) of drug-free schizophrenics, this relationship was highly significant (r = 0.59, p <0.001). These clinical data are consistent with preclinical evidence indicating a functional interaction between CMS somatostatin and dopamine systems.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 431-439 |
| Number of pages | 9 |
| Journal | Biological Psychiatry |
| Volume | 25 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 15 1989 |
| Externally published | Yes |
ASJC Scopus subject areas
- Biological Psychiatry
Fingerprint Dive into the research topics of 'Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA'. Together they form a unique fingerprint.
Cite this
Doran, A. R., Rubinow, D. R., Wolkowitz, O. M., Roy, A., Breier, A., & Pickar, D. (1989). Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA. Biological Psychiatry, 25(4), 431-439. https://doi.org/10.1016/0006-3223(89)90196-0